Zhejiang University has disclosed transient receptor potential cation channel subfamily M member 2 (TRPM2) antagonists reported to be useful for the treatment of stroke and ischemia-reperfusion injury, among others.

Terns Pharmaceuticals Inc. has patented thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of nonalcoholic steatohepatitis.

University of Michigan has described new proteolysis targeting chimeric (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to CREB-binding protein (CBP) and/or histone acetyltransferase KAT3B (p300)-targeting moiety through linker reported to be useful for the treatment of cancer.

Eli Lilly & Co. has synthesized macrocyclic peptides acting as amylin receptor agonists, glucose- and/or triglyceride-lowering agents reported to be useful for the treatment of type 2 diabetes, obesity, dyslipidemia and nonalcoholic steatohepatitis.

Kumquat Biosciences Inc. has divulged son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.

Dana-Farber Cancer Institute Inc. has disclosed epidermal growth factor receptor (EGFR) and mutant inhibitors reported to be useful for the treatment of cancer.

Flare Therapeutics Inc. has synthesized peroxisome proliferator-activated receptor γ (PPARγ) inverse agonists reported to be useful for the treatment of bladder cancer.

Hitgen Ltd. has divulged NUAK family SNF1-like kinase 1 (NUAK1) and/or NUAK family SNF1-like kinase 2 (NUAK2) inhibitors reported to be useful for the treatment of cancer.

Viva Star Biosciences Ltd. has presented son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.